| Year |
Citation |
Score |
| 2024 |
Rodriguez GM, Yakubovich E, Murshed H, Maranda V, Galpin KJC, Cudmore A, Hanna AMR, Macdonald E, Ramesh S, Garson K, Vanderhyden BC. NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens. Frontiers in Immunology. 14: 1295208. PMID 38235131 DOI: 10.3389/fimmu.2023.1295208 |
0.387 |
|
| 2024 |
Galpin KJC, Rodriguez GM, Maranda V, Cook DP, Macdonald E, Murshed H, Zhao S, McCloskey CW, Chruscinski A, Levy GA, Ardolino M, Vanderhyden BC. FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models. Scientific Reports. 14: 787. PMID 38191799 DOI: 10.1038/s41598-024-51217-1 |
0.38 |
|
| 2023 |
Yakubovich E, Cook DP, Rodriguez GM, Vanderhyden BC. Mesenchymal ovarian cancer cells promote CD8 T cell exhaustion through the LGALS3-LAG3 axis. Npj Systems Biology and Applications. 9: 61. PMID 38086828 DOI: 10.1038/s41540-023-00322-4 |
0.404 |
|
| 2023 |
Rodriguez GM, Yakubovich E, Vanderhyden BC. Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success. Cancers. 15. PMID 38067396 DOI: 10.3390/cancers15235694 |
0.399 |
|
| 2023 |
Cook DP, Galpin KJC, Rodriguez GM, Shakfa N, Wilson-Sanchez J, Echaibi M, Pereira M, Matuszewska K, Haagsma J, Murshed H, Cudmore AO, MacDonald E, Tone A, Shepherd TG, Petrik JJ, ... ... Vanderhyden BC, et al. Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer. Communications Biology. 6: 1152. PMID 37957414 DOI: 10.1038/s42003-023-05529-z |
0.34 |
|
| 2023 |
Wong B, Bergeron A, Maznyi G, Ng K, Jirovec A, Birdi HK, Serrano D, Spinelli M, Thomson M, Taha Z, Alwithenani A, Chen A, Lorimer I, Vanderhyden B, Arulanandam R, et al. Pevonedistat, a First in-class NEDD8-activating Enzyme Inhibitor, sensitizes cancer cells to VSVΔ51 Oncolytic Virotherapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 37766429 DOI: 10.1016/j.ymthe.2023.09.017 |
0.311 |
|
| 2023 |
Surendran A, Jamalkhah M, Poutou J, Birtch R, Lawson C, Dave J, Crupi MJF, Mayer J, Taylor V, Petryk J, de Souza CT, Moodie N, Billingsley JL, Austin B, Cormack N, ... ... Vanderhyden B, et al. Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy lipid modulation of the tumor microenvironment. Frontiers in Immunology. 14: 1099459. PMID 36969187 DOI: 10.3389/fimmu.2023.1099459 |
0.325 |
|
| 2022 |
Rodriguez GM, Galpin KJC, Cook DP, Yakubovich E, Maranda V, Macdonald EA, Wilson-Sanchez J, Thomas AL, Burdette JE, Vanderhyden BC. The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research. Cancer Research Communications. 2: 417-433. PMID 36311166 DOI: 10.1158/2767-9764.crc-22-0017 |
0.414 |
|
| 2022 |
Alwosaibai K, Al-Hujaily EM, Alamri S, Ghandorah S, Garson K, Vanderhyden BC. PAX2 induces vascular-like structures in normal ovarian cells and ovarian cancer. Experimental and Therapeutic Medicine. 23: 412. PMID 35601066 DOI: 10.3892/etm.2022.11339 |
0.487 |
|
| 2022 |
Cook DP, Vanderhyden BC. Transcriptional census of epithelial-mesenchymal plasticity in cancer. Science Advances. 8: eabi7640. PMID 34985957 DOI: 10.1126/sciadv.abi7640 |
0.326 |
|
| 2021 |
David S, Plante A, Dallaire F, Tremblay JP, Sheehy G, Macdonald E, Forrest L, Daneshmand M, Trudel D, Wilson BC, Hopkins L, Murugkar S, Vanderhyden B, Leblond F. Multispectral label-free Raman spectroscopy can detect ovarian and endometrial cancer with high accuracy. Journal of Biophotonics. e202100198. PMID 34837331 DOI: 10.1002/jbio.202100198 |
0.344 |
|
| 2021 |
Alkailani M, Palidwor G, Poulin A, Mohan R, Pepin D, Vanderhyden B, Gibbings D. A genome-wide strategy to identify causes and consequences of retrotransposon expression finds activation by BRCA1 in ovarian cancer. Nar Cancer. 3: zcaa040. PMID 33447827 DOI: 10.1093/narcan/zcaa040 |
0.425 |
|
| 2020 |
Landry DA, Vaishnav HT, Vanderhyden BC. The significance of ovarian fibrosis. Oncotarget. 11: 4366-4370. PMID 33315987 DOI: 10.18632/oncotarget.27822 |
0.397 |
|
| 2020 |
Mehdi S, Macdonald E, Galpin K, Landry DA, Rodriguez G, Vanderhyden B, Bachvarov D. LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model. International Journal of Molecular Sciences. 21. PMID 32679765 DOI: 10.3390/Ijms21144992 |
0.448 |
|
| 2020 |
Kim O, Park EY, Klinkebiel DL, Pack SD, Shin YH, Abdullaev Z, Emerson RE, Coffey DM, Kwon SY, Creighton CJ, Kwon S, Chang EC, Chiang T, Yatsenko AN, Chien J, ... ... Vanderhyden B, et al. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. Plos Genetics. 16: e1008808. PMID 32497036 DOI: 10.1371/Journal.Pgen.1008808 |
0.506 |
|
| 2020 |
Arulanandam R, Taha Z, Garcia V, Selman M, Chen A, Varette O, Jirovec A, Sutherland K, Macdonald E, Tzelepis F, Birdi H, Alluqmani N, Landry A, Bergeron A, Vanderhyden B, et al. The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy. Communications Biology. 3: 254. PMID 32444806 DOI: 10.1038/s42003-020-0972-7 |
0.302 |
|
| 2020 |
Al-Zahrani KN, Abou-Hamad J, Cook DP, Pryce BR, Hodgins JJ, Labrèche C, Robineau-Charette P, de Souza CT, Bell JC, Auer RC, Ardolino M, Vanderhyden BC, Sabourin LA. Loss of the Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers. Oncogene. PMID 32393835 DOI: 10.1038/s41388-020-1315-3 |
0.358 |
|
| 2020 |
Feng Y, Tang Y, Mao Y, Liu Y, Yao D, Yang L, Garson K, Vanderhyden BC, Wang Q. PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming. International Journal of Oncology. PMID 31922217 DOI: 10.3892/Ijo.2020.4958 |
0.446 |
|
| 2020 |
Al-Zahrani KN, Abou-Hamad J, Pryce B, Cook DP, Hodgins J, Labreche C, Robineau-Charette P, Souza Cd, Bell J, Auer R, Ardolino M, Vanderhyden B, Schramek D, Sabourin L. Abstract P2-04-05: Loss of Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P2-04-05 |
0.322 |
|
| 2019 |
McCloskey CW, Cook DP, Kelly BS, Azzi F, Allen CH, Forsyth-Greig A, Upham J, Rayner KJ, Gray DA, Boyd RW, Murugkar S, Lo B, Trudel D, Senterman MK, Vanderhyden BC. Metformin abrogates age-associated ovarian fibrosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31597663 DOI: 10.1158/1078-0432.Ccr-19-0603 |
0.349 |
|
| 2019 |
St-Jean G, Tsoi M, Abedini A, Levasseur A, Rico C, Morin M, Djordjevic B, Miinalainen I, Kaarteenaho R, Paquet M, Gévry N, Boyer A, Vanderhyden B, Boerboom D. and are required for the maintenance of multipotency in the Müllerian duct mesenchyme. Development (Cambridge, England). PMID 31575647 DOI: 10.1242/Dev.180430 |
0.335 |
|
| 2019 |
Cook DP, Vanderhyden BC. Ovarian cancer and the evolution of subtype classifications using transcriptional profiling. Biology of Reproduction. PMID 31187121 DOI: 10.1093/biolre/ioz099 |
0.443 |
|
| 2019 |
Sheta R, Bachvarova M, Macdonald E, Gobeil S, Vanderhyden B, Bachvarov D. The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression. International Journal of Molecular Sciences. 20. PMID 31071912 DOI: 10.3390/Ijms20092264 |
0.48 |
|
| 2019 |
Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQD, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson RM, Cencic R, Patibandla J, ... ... Vanderhyden B, et al. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nature Communications. 10: 558. PMID 30718512 DOI: 10.1038/S41467-018-06958-9 |
0.36 |
|
| 2018 |
Vuong NH, Cook DP, Forrest LA, Carter LE, Robineau-Charette P, Kofsky JM, Hodgkinson KM, Vanderhyden BC. Single-cell RNA-sequencing reveals transcriptional dynamics of estrogen-induced dysplasia in the ovarian surface epithelium. Plos Genetics. 14: e1007788. PMID 30418965 DOI: 10.1371/journal.pgen.1007788 |
0.434 |
|
| 2018 |
Al-Zahrani KN, Cook DP, Vanderhyden BC, Sabourin LA. Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling. Oncotarget. 9: 33348-33359. PMID 30279965 DOI: 10.18632/oncotarget.26072 |
0.334 |
|
| 2018 |
McCloskey CW, Rodriguez GM, Galpin KJC, Vanderhyden BC. Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. Cancers. 10. PMID 30049987 DOI: 10.3390/cancers10080244 |
0.467 |
|
| 2018 |
Rodriguez GM, Galpin KJC, McCloskey CW, Vanderhyden BC. The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy. Cancers. 10. PMID 30042343 DOI: 10.3390/cancers10080242 |
0.465 |
|
| 2018 |
Hodgkinson K, Forrest LA, Vuong N, Garson K, Djordjevic B, Vanderhyden BC. GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer. Oncogene. PMID 29973689 DOI: 10.1038/s41388-018-0377-y |
0.506 |
|
| 2018 |
Hasim MS, Nessim C, Villeneuve PJ, Vanderhyden BC, Dimitroulakos J. Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer. Translational Oncology. 11: 988-998. PMID 29940414 DOI: 10.1016/J.Tranon.2018.06.001 |
0.328 |
|
| 2018 |
Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, ... ... Vanderhyden B, et al. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. Bmc Cancer. 18: 347. PMID 29587661 DOI: 10.1186/S12885-018-4242-8 |
0.348 |
|
| 2017 |
Vuong NH, Salah Salah O, Vanderhyden BC. 17β-Estradiol sensitizes ovarian surface epithelium to transformation by suppressing Disabled-2 expression. Scientific Reports. 7: 16702. PMID 29196616 DOI: 10.1038/s41598-017-16219-2 |
0.508 |
|
| 2017 |
Sheta R, Wang ZQ, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Gobeil S, Morin C, Macdonald E, Vanderhyden B, Bachvarov D. Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFβ1-independent manner. Oncotarget. 8: 82506-82530. PMID 29137281 DOI: 10.18632/Oncotarget.19714 |
0.49 |
|
| 2016 |
Moradi H, Ahmad A, Shepherdson D, Vuong NH, Niedbala G, Eapen L, Vanderhyden B, Nyiri B, Murugkar S. Raman micro-spectroscopy applied to treatment resistant and sensitive human ovarian cancer cells. Journal of Biophotonics. PMID 28009133 DOI: 10.1002/Jbio.201600211 |
0.397 |
|
| 2016 |
Köbel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, de Ladurantaye M, Lee S, Leung S, Goode EL, Ramus SJ, Carlson JW, Li X, Ewanowich CA, Kelemen LE, ... Vanderhyden B, et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. PMID 26974996 DOI: 10.1097/Pgp.0000000000000274 |
0.377 |
|
| 2016 |
Bernaudo S, Salem M, Qi X, Zhou W, Zhang C, Yang W, Rosman D, Deng Z, Ye G, Yang B, Vanderhyden B, Wu Z, Peng C. Cyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/β-catenin signaling. Oncogene. PMID 26876206 DOI: 10.1038/Onc.2016.15 |
0.322 |
|
| 2016 |
Faddaoui A, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Gobeil S, Morin C, Macdonald E, Vanderhyden B, Bachvarov D. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells. Oncotarget. 7: 14125-42. PMID 26871602 DOI: 10.18632/Oncotarget.7288 |
0.494 |
|
| 2015 |
Al-Hujaily EM, Tang Y, Yao DS, Carmona E, Garson K, Vanderhyden BC. Divergent roles of PAX2 in the etiology and progression of ovarian cancer. Cancer Prevention Research (Philadelphia, Pa.). PMID 26373819 DOI: 10.1158/1940-6207.CAPR-15-0121-T |
0.48 |
|
| 2015 |
Wang ZQ, Faddaoui A, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Guillemette C, Gobeil S, Macdonald E, Vanderhyden B, Bachvarov D. BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism. Oncotarget. 6: 31522-43. PMID 26372729 DOI: 10.18632/Oncotarget.5159 |
0.55 |
|
| 2015 |
Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression. Oncotarget. 6: 27613-27. PMID 26243836 DOI: 10.18632/oncotarget.4546 |
0.48 |
|
| 2015 |
Eddie SL, Quartuccio SM, hAinmhire EÓ, Moyle-Heyrman G, Lantvit DD, Wei JJ, Vanderhyden BC, Burdette JE. Tumorigenesis and peritoneal colonization from fallopian tube epithelium. Oncotarget. PMID 25971410 DOI: 10.18632/Oncotarget.3985 |
0.394 |
|
| 2015 |
Arulanandam R, Batenchuk C, Varette O, Zakaria C, Garcia V, Forbes NE, Davis C, Krishnan R, Karmacharya R, Cox J, Sinha A, Babawy A, Waite K, Weinstein E, Falls T, ... ... Vanderhyden B, et al. Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nature Communications. 6: 6410. PMID 25817275 DOI: 10.1038/Ncomms7410 |
0.441 |
|
| 2015 |
Ali AY, Kim JY, Pelletier JF, Vanderhyden BC, Bachvarov DR, Tsang BK. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. Molecular Carcinogenesis. 54: 1301-14. PMID 25154814 DOI: 10.1002/mc.22205 |
0.398 |
|
| 2014 |
Hodgkinson KM, Vanderhyden BC. Consideration of GREB1 as a potential therapeutic target for hormone-responsive or endocrine-resistant cancers. Expert Opinion On Therapeutic Targets. 18: 1065-76. PMID 24998469 DOI: 10.1517/14728222.2014.936382 |
0.397 |
|
| 2014 |
McCloskey CW, Goldberg RL, Carter LE, Gamwell LF, Al-Hujaily EM, Collins O, Macdonald EA, Garson K, Daneshmand M, Carmona E, Vanderhyden BC. A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population. Frontiers in Oncology. 4: 53. PMID 24672774 DOI: 10.3389/fonc.2014.00053 |
0.445 |
|
| 2014 |
Ribeiro JR, Lovasco LA, Vanderhyden BC, Freiman RN. Targeting TBP-Associated Factors in Ovarian Cancer. Frontiers in Oncology. 4: 45. PMID 24653979 DOI: 10.3389/Fonc.2014.00045 |
0.485 |
|
| 2014 |
Laviolette LA, Hodgkinson KM, Minhas N, Perez-Iratxeta C, Vanderhyden BC. 17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo. International Journal of Cancer. Journal International Du Cancer. 135: 1072-84. PMID 24469735 DOI: 10.1002/Ijc.28741 |
0.785 |
|
| 2014 |
Ribeiro JR, Lovasco LA, Vanderhyden BC, Freiman RN. Targeting TBP-associated factors in ovarian cancer Frontiers in Oncology. 4. DOI: 10.3389/fonc.2014.00045 |
0.335 |
|
| 2014 |
Hodgkinson K, Laviolette L, Vanderhyden B. 322: Identification of GREB1 as a potential mediator of estrogen effects on ovarian cancer progression in a mouse model European Journal of Cancer. 50: S77. DOI: 10.1016/S0959-8049(14)50287-0 |
0.469 |
|
| 2013 |
Abdallah BY, Horne SD, Stevens JB, Liu G, Ying AY, Vanderhyden B, Krawetz SA, Gorelick R, Heng HH. Single cell heterogeneity: why unstable genomes are incompatible with average profiles. Cell Cycle (Georgetown, Tex.). 12: 3640-9. PMID 24091732 DOI: 10.4161/Cc.26580 |
0.37 |
|
| 2013 |
Wardell JR, Hodgkinson KM, Binder AK, Seymour KA, Korach KS, Vanderhyden BC, Freiman RN. Estrogen responsiveness of the TFIID subunit TAF4B in the normal mouse ovary and in ovarian tumors Biology of Reproduction. 89. PMID 24068106 DOI: 10.1095/Biolreprod.113.111336 |
0.49 |
|
| 2013 |
Gamwell LF, Gambaro K, Merziotis M, Crane C, Arcand SL, Bourada V, Davis C, Squire JA, Huntsman DG, Tonin PN, Vanderhyden BC. Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet Journal of Rare Diseases. 8: 33. PMID 23433318 DOI: 10.1186/1750-1172-8-33 |
0.37 |
|
| 2013 |
King SM, Quartuccio SM, Vanderhyden BC, Burdette JE. Early transformative changes in normal ovarian surface epithelium induced by oxidative stress require Akt upregulation, DNA damage and epithelial-stromal interaction. Carcinogenesis. 34: 1125-33. PMID 23299406 DOI: 10.1093/Carcin/Bgt003 |
0.321 |
|
| 2012 |
Garson K, Gamwell LF, Pitre EM, Vanderhyden BC. Technical challenges and limitations of current mouse models of ovarian cancer. Journal of Ovarian Research. 5: 39. PMID 23190474 DOI: 10.1186/1757-2215-5-39 |
0.345 |
|
| 2012 |
Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, ... ... Vanderhyden BC, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers Molecular Therapy. 20: 749-758. PMID 22186794 DOI: 10.1038/mt.2011.276 |
0.402 |
|
| 2012 |
Aguirre MG, Chabot J, So R, Chaparro LES, Yan FJ, Garson K, Vanderhyden B, Sokoll KK. Abstract 2907: Novel liposomal compositions of PharmaGap's lead peptide: Effect on ovarian cancer cell proliferation and signaling pathways Cancer Research. 72: 2907-2907. DOI: 10.1158/1538-7445.Am2012-2907 |
0.412 |
|
| 2012 |
Vuong NH, Macdonald E, Hodgkinson K, Laviolette LA, Vanderhyden BC. Mechanisms by Which Estrogen Accelerates Ovarian Tumor Initiation. Biology of Reproduction. 87: 548-548. DOI: 10.1093/Biolreprod/87.S1.548 |
0.748 |
|
| 2012 |
Wardell JR, Hodgkinson K, Seymour KA, O'Brien CW, Vanderhyden BC, Freiman RN. TAF4b Is Induced by Estrogen in the Normal Mouse Ovary and During Estrogen-Supplemented Ovarian Tumorigenesis. Biology of Reproduction. 87: 536-536. DOI: 10.1093/Biolreprod/87.S1.536 |
0.365 |
|
| 2011 |
Pépin D, Shao ZQ, Huppé G, Wakefield A, Chu CW, Sharif Z, Vanderhyden BC. Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model. Plos One. 6: e26075. PMID 22102857 DOI: 10.1371/journal.pone.0026075 |
0.475 |
|
| 2011 |
Laviolette LA, Ethier JF, Senterman MK, Devine PJ, Vanderhyden BC. Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Menopause (New York, N.Y.). 18: 549-57. PMID 21221022 DOI: 10.1097/Gme.0B013E3181Fca1B6 |
0.783 |
|
| 2011 |
Hodgkinson KM, Laviolette L, Perez-Iratxeta C, Vanderhyden BC. Reproductive Steroid Hormones Alter Ovarian Cancer Progression in Mouse Models. Biology of Reproduction. 85: 343-343. DOI: 10.1093/Biolreprod/85.S1.343 |
0.778 |
|
| 2011 |
Vanderhyden BC, Laviolette L, Hodgkinson K, Garson K. Lessons Learned from Mouse Models of Ovarian Cancer. Biology of Reproduction. 85: 15-15. DOI: 10.1093/BIOLREPROD/85.S1.15 |
0.317 |
|
| 2010 |
Laviolette LA, Garson K, Macdonald EA, Senterman MK, Courville K, Crane CA, Vanderhyden BC. 17beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology. 151: 929-38. PMID 20056833 DOI: 10.1210/en.2009-0602 |
0.791 |
|
| 2009 |
Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. Plos One. 4: e8534. PMID 20046869 DOI: 10.1371/journal.pone.0008534 |
0.382 |
|
| 2009 |
Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, ... ... Vanderhyden B, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. The New England Journal of Medicine. 360: 2719-29. PMID 19516027 DOI: 10.1056/Nejmoa0902542 |
0.364 |
|
| 2008 |
Weberpals JI, Clark-Knowles KV, Vanderhyden BC. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3259-67. PMID 18591560 DOI: 10.1200/JCO.2007.11.3902 |
0.328 |
|
| 2008 |
Salehi F, Dunfield L, Phillips KP, Krewski D, Vanderhyden BC. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. Journal of Toxicology and Environmental Health. Part B, Critical Reviews. 11: 301-21. PMID 18368558 DOI: 10.1080/10937400701876095 |
0.409 |
|
| 2008 |
Shaw TJ, Lacasse EC, Durkin JP, Vanderhyden BC. Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. International Journal of Cancer. 122: 1430-4. PMID 18027851 DOI: 10.1002/ijc.23278 |
0.468 |
|
| 2008 |
Laviolette LA, Garson K, Macdonald EA, Senterman MK, Courville K, Vanderhyden BC. Exogenous 17β-estradiol Results in an Earlier Onset of Ovarian Cancer and a Decreased Survival Time in a Transgenic Mouse Model of Ovarian Cancer. Biology of Reproduction. 78: 179-179. DOI: 10.1093/Biolreprod/78.S1.179 |
0.767 |
|
| 2007 |
Shaw TJ, Vanderhyden BC. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate. Gynecologic Oncology. 105: 122-31. PMID 17169414 DOI: 10.1016/j.ygyno.2006.10.052 |
0.496 |
|
| 2007 |
Clark-Knowles KV, Garson K, Jonkers J, Vanderhyden BC. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Experimental Cell Research. 313: 133-45. PMID 17070800 DOI: 10.1016/j.yexcr.2006.09.026 |
0.343 |
|
| 2006 |
Yao DS, Li L, Garson K, Vanderhyden BC. [*OPCML gene transferred by recombinant lentiviruses in vitro and its inhibition to ovarian cancer cells]. Zhonghua Fu Chan Ke Za Zhi. 41: 333-8. PMID 16762191 |
0.374 |
|
| 2006 |
Chambers AF, Vanderhyden BC. Ovarian cancer biomarkers in urine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 323-7. PMID 16428467 DOI: 10.1158/1078-0432.CCR-05-2563 |
0.387 |
|
| 2005 |
Garson K, Shaw TJ, Clark KV, Yao DS, Vanderhyden BC. Models of ovarian cancer--are we there yet? Molecular and Cellular Endocrinology. 239: 15-26. PMID 15955618 DOI: 10.1016/j.mce.2005.03.019 |
0.491 |
|
| 2005 |
Vanderhyden BC. Loss of ovarian function and the risk of ovarian cancer. Cell and Tissue Research. 322: 117-24. PMID 15902502 DOI: 10.1007/s00441-005-1100-1 |
0.451 |
|
| 2005 |
Steller MD, Shaw TJ, Vanderhyden BC, Ethier JF. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Molecular Cancer Research : McR. 3: 50-61. PMID 15671249 |
0.498 |
|
| 2004 |
Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 1032-42. PMID 15564135 DOI: 10.1016/j.ymthe.2004.08.013 |
0.474 |
|
| 2003 |
Hamilton TC, Connolly DC, Nikitin AY, Garson K, Vanderhyden BC. Translational research in ovarian cancer: A must International Journal of Gynecological Cancer. 13: 220-230. PMID 14656284 DOI: 10.1111/J.1525-1438.2003.13350.X |
0.44 |
|
| 2003 |
Vanderhyden BC, Shaw TJ, Ethier JF. Animal models of ovarian cancer. Reproductive Biology and Endocrinology : Rb&E. 1: 67. PMID 14613552 DOI: 10.1186/1477-7827-1-67 |
0.469 |
|
| 2003 |
Garson K, Macdonald E, Dubé M, Bao R, Hamilton TC, Vanderhyden BC. Generation of tumors in transgenic mice expressing the SV40 T antigen under the control of ovarian-specific promoter 1. Journal of the Society For Gynecologic Investigation. 10: 244-50. PMID 12759154 DOI: 10.1016/S1071-5576(03)00073-X |
0.368 |
|
| 2003 |
Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Research. 63: 1389-97. PMID 12649204 |
0.452 |
|
| 2003 |
Hamilton TC, Connolly DC, Nikitin AY, Garson K, Vanderhyden BC. Translational research in ovarian cancer: a must International Journal of Gynecologic Cancer. 13: 220-230. DOI: 10.1136/ijgc-00009577-200311001-00016 |
0.44 |
|
| 2002 |
Vanderhyden B. Molecular basis of ovarian development and function. Frontiers in Bioscience : a Journal and Virtual Library. 7: d2006-22. PMID 12161348 DOI: 10.2741/Vander |
0.443 |
|
| 2002 |
Shaw TJ, Keszthelyi EJ, Tonary AM, Cada M, Vanderhyden BC. Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression. Experimental Cell Research. 273: 95-106. PMID 11795950 DOI: 10.1006/Excr.2001.5426 |
0.76 |
|
| 2001 |
Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, Vanderhyden B, Faught W, Fung MFK, Senterman M, Korneluk RG, Tsang BK. Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins Endocrinology. 142: 370-380. PMID 11145600 DOI: 10.1210/Endo.142.1.7897 |
0.432 |
|
| 2000 |
Tonary AM, Macdonald EA, Faught W, Senterman MK, Vanderhyden BC. Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. International Journal of Cancer. Journal International Du Cancer. 89: 242-50. PMID 10861500 DOI: 10.1002/1097-0215(20000520)89:3<242::Aid-Ijc6>3.0.Co;2-6 |
0.753 |
|
| 1998 |
Vanderhyden BC, Macdonald EA. Mouse oocytes regulate granulosa cell steroidogenesis throughout follicular development. Biology of Reproduction. 59: 1296-301. PMID 9828170 DOI: 10.1095/BIOLREPROD59.6.1296 |
0.304 |
|
| 1998 |
TSANG B, LI J, FENG Q, LISTON P, KIM J, SCHNEIDERMAN D, SENTERMAN M, VANDERHYDEN B, FAUGHT W, FUNG M. Regulation of apoptosis in human ovarian cancer Journal of the Society For Gynecologic Investigation. 5: 46A-46A. DOI: 10.1016/S1071-5576(97)86107-2 |
0.47 |
|
| 1997 |
Ismail RS, Dubé M, Vanderhyden BC. Hormonally regulated expression and alternative splicing of kit ligand may regulate kit-induced inhibition of meiosis in rat oocytes. Developmental Biology. 184: 333-42. PMID 9133439 DOI: 10.1006/DBIO.1997.8531 |
0.323 |
|
| 1995 |
Vanderhyden BC, Tonary AM. Differential regulation of progesterone and estradiol production by mouse cumulus and mural granulosa cells by A factor(s) secreted by the oocyte. Biology of Reproduction. 53: 1243-50. PMID 8562677 DOI: 10.1095/Biolreprod53.6.1243 |
0.725 |
|
| Show low-probability matches. |